Pith. sign in

REVIEW 4 major objections 4 minor 11 references

Computational Analysis using Multi-ligand Simultaneous Docking of Withaferin A and Garcinol Reveals Enhanced BCL-2 and AKT-1 Inhibition

T0 review · 4 major / 4 minor · reviewed 2026-08-15 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗ Review JSON

Pith's one-line read Withaferin A and garcinol docked together yield more negative BCL-2 and AKT-1 binding scores than venetoclax or melatonin.

desk verdict Routine MLSD docking study whose headline claim fails: a two-ligand total score cannot be compared to single-ligand reference scores to infer enhanced inhibition. read the letter →

arxiv 2505.08632 v1 pith:ICMLXKT5 submitted 2025-05-13 q-bio.BM

Pronama Biswas , Dishali Mathur , Jinal Dinesh , Hitesh Kumar Dinesh , Belaguppa Manjunath Ashwin Desai This is my paper · ORCID
classification q-bio.BM
keywords withaferinAgarcinolBCL-2AKT-1multi-ligandsimultaneousdockingsynergisticinhibitioncancertargetsphytochemicalcombination
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

This paper tries to show that two plant-derived compounds, withaferin A from ashwagandha and garcinol from kokum, inhibit the cancer-survival proteins BCL-2 and AKT-1 more strongly when they are docked together than either reference inhibitor does alone. The argument is carried by multi-ligand simultaneous docking, a calculation that places both molecules in the binding pocket at once and lets them touch each other as well as the protein. The reported combined binding affinities are $-11.88 \pm 0.12$ kcal/mol for BCL-2 versus $-9.73 \pm 0.1$ for venetoclax, and $-13.74 \pm 0.08$ kcal/mol for AKT-1 versus $-7.24 \pm 0.06$ for melatonin, which the authors interpret as an additive or synergistic dual inhibition. The paper frames the result as an early in-silico step toward a two-molecule, two-target cancer strategy using widely available dietary compounds, and it calls for experimental validation.

What carries the argument

The load-bearing object is multi-ligand simultaneous docking (MLSD), in which two ligand molecules are docked into the same receptor pocket at the same time so that ligand-ligand contacts can contribute to the final score. In this study it is the mechanism that generates the enhanced binding affinities: the inter-ligand $\pi$-alkyl interaction observed against BCL-2, and the side-by-side occupation of the AKT-1 pocket, are what distinguish the pair's result from two independent single-ligand dockings. The estimated binding affinity reported in kcal/mol is the quantity used to compare the pair against venetoclax and melatonin.

What would settle it

Dock withaferin A and garcinol separately into the same BCL-2 and AKT-1 structures, add their two best single-ligand energies, and compare the sum with the MLSD score; if the sum is within the reported uncertainty, the simultaneous docking gain carries no evidence of inter-ligand synergy. A cell-based assay comparing the pair with each compound alone would then settle whether any functional inhibition matches the docking ranking.

Watch

Extended reading notes

Core claim

In the paper's own terms, the central result is that multi-ligand simultaneous docking of withaferin A and garcinol produces more negative binding affinities than the commercial inhibitors: $-11.88 \pm 0.12$ kcal/mol against BCL-2 compared with $-9.73 \pm 0.1$ kcal/mol for venetoclax, and $-13.74 \pm 0.08$ kcal/mol against AKT-1 compared with $-7.24 \pm 0.06$ kcal/mol for melatonin. For BCL-2, the authors attribute the gain to an inter-ligand $\pi$-alkyl contact between the two phytochemicals inside the same pocket used by venetoclax. For AKT-1, they report that garcinol occupies the melatonin pocket while withaferin A binds in an adjacent region, and they describe the combined effect as additive or synergistic. The authors conclude that the pair shows a synergistic inhibitory effect on both targets and treat the docking energies as evidence of dual inhibition.

Load-bearing premise

The central comparison assumes that a two-ligand simultaneous docking score can be read in the same units and with the same meaning as a single-ligand reference docking score, so that a more negative value directly indicates enhanced inhibition.

Editorial extensions

If this is right

  • If the MLSD scores are accurate predictors, the withaferin A-garcinol pair becomes a computational lead for dual BCL-2/AKT-1 inhibition in cancers that rely on apoptosis evasion and PI3K/AKT signaling.
  • The reported $\pi$-alkyl inter-ligand contact against BCL-2 implies that co-formulation or a linked hybrid of the two compounds could stabilize the bound complex better than either compound alone.
  • The AKT-1 pose, with garcinol in the melatonin pocket and withaferin A adjacent, suggests the pair could occupy neighboring sites without competing, which may help counter resistance caused by mutations in one binding site.
  • The authors' dual-inhibition conclusion points to testing the combination in cell lines that overexpress both BCL-2 and AKT-1, such as the cervical and ovarian contexts cited for the individual compounds.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • A natural next calculation the paper leaves undone is to compare the MLSD score against the sum of the two single-ligand scores; that difference would separate true cooperativity from the arithmetic effect of placing two molecules in one pocket.
  • The same simultaneous-docking protocol could be used as a cheap screen for other natural-product pairs against oncogenic targets, generating combination candidates before any wet-lab work.
  • Because the authors find no inter-ligand contact in the AKT-1 pose, the AKT-1 result may reflect adjacent-pocket occupancy rather than mutual stabilization; the BCL-2 and AKT-1 mechanisms would then need different optimization strategies.
Share X Bluesky LinkedIn Reddit HN

Signed reviews

No signed human review yet.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

4 major / 4 minor

Summary. The manuscript reports AutoDock Vina single-ligand and multi-ligand simultaneous docking (MLSD) of withaferin A and garcinol against BCL-2 and AKT-1, compares the MLSD binding scores with those of venetoclax and melatonin, and concludes that the combination exhibits enhanced and synergistic inhibition of both targets. The paper includes methods details, docking scores, 2D/3D interaction analyses, and a limitation statement acknowledging the need for experimental validation.

Significance. If the claimed enhanced dual inhibition were established, the work would offer a computational rationale for combining these two natural products in cancer therapy. The paper is clearly structured and provides reproducible command-level details, and the authors appropriately list PAINS filtering and explicit limitations. However, the central quantitative claim rests on comparing an MLSD score for two ligands with single-ligand scores of reference inhibitors, a comparison that is not physically meaningful. Because the main conclusion depends on this invalid comparison and there is no experimental or molecular dynamics support, the significance of the findings is not currently established.

major comments (4)
  1. [III-B; Abstract; Conclusion] The central claim that the MLSD scores (-11.88 ± 0.12 kcal/mol for BCL-2; -13.74 ± 0.08 kcal/mol for AKT-1) 'surpass' venetoclax (-9.73 ± 0.1 kcal/mol) and melatonin (-7.24 ± 0.06 kcal/mol) is based on comparing a two-ligand complex score with a one-ligand score. Vina's output for MLSD is the total energy of the receptor with both ligands and includes ligand-ligand terms; it does not measure the affinity of either individual ligand, and it naturally scales with ligand size and number of rotatable bonds. This invalid comparison is the sole quantitative evidence for 'enhanced inhibition.' The paper itself states (Section III-B) that in AKT-1, withaferin A is positioned adjacent to the melatonin pocket 'without any interactions with the amino acids of the original binding site,' so a substantial part of the AKT-1 MLSD score reflects a secondary, non-conserved contact. To support the claim, the authors would need per-ligand affinity decomposition, a size-matched control, or an experimental/functional readout.
  2. [II-A; Table I] The BCL-2 structure is given as PDB ID 4WJ9 in Methods II-A, but Table I reports the BCL-2 PDB ID as 8HOG. These are different structures (a mouse BCL-2 in complex with a peptide versus a human BCL-2 construct). This discrepancy affects every BCL-2 result in the paper and prevents reproduction. The authors must state which structure was actually used and ensure consistency throughout.
  3. [III-B; Discussion] The conclusion of a 'synergistic inhibitory effect' is supported only by the observation of one pi-alkyl inter-ligand interaction in the BCL-2 MLSD pose (and no inter-ligand interaction in AKT-1). A single contact is not evidence of cooperativity or synergy; no thermodynamic coupling, dose-response, or functional assay is provided. The term 'synergistic' is therefore an overinterpretation of the docking output; at most the data demonstrate simultaneous occupancy of the pocket.
  4. [Discussion (limitations)] The manuscript includes a limitation paragraph acknowledging that computational docking requires experimental validation and that missing residues and 'speculations' may affect results. This is appropriately candid, but the abstract and conclusion still state as a finding that the combination 'reveals enhanced BCL-2 and AKT-1 inhibition.' The acknowledged limitations do not repair the invalid comparison; they underscore that the headline claim is not supported by the evidence presented.
minor comments (4)
  1. [III-B] In the sentence 'surpassed the binding affinity of venetoclax (9.73±0.1 kcal/mol)', the minus sign is missing; it should read -9.73 ± 0.1 kcal/mol.
  2. [III-A] The paper reports that garcinol has one PAINS alert (Catechol A); the potential implications of this alert for the claimed target specificity are not discussed.
  3. [Table I] The table caption could state the number of independent docking runs used to compute the mean ± standard deviation, since this information is not provided in the Methods.
  4. [Figures] Figures 3 and 4 would be easier to evaluate if the shared amino acids mentioned in the captions were explicitly labeled in the rendered panels.

Circularity Check

0 steps flagged · score 0.0 of 10

No circularity: the docking scores are external tool outputs and no derived quantity reduces to an input fit or self-citation.

full rationale

I walked the derivation chain: the paper runs AutoDock Vina single-ligand and MLSD docking on PDB structures and PubChem ligands, then compares the reported scores. There is no fitted parameter renamed as a prediction, no quantity defined in terms of the target quantity, and no load-bearing citation to the authors' own prior work. The MLSD versus single-ligand comparison may be scientifically debatable because adding a second ligand changes the number of atoms and interaction terms in Vina's scoring function; that is a normalization or commensurability concern, not a circularity: the -11.88 and -13.74 kcal/mol scores are outputs of an externally developed scoring function, not constructed to equal the reference values. The authors also explicitly disclaim experimental validation in their limitations paragraph, which is the appropriate non-circular statement that docking predictions require wet-lab confirmation. No step in the paper's own text reduces to its inputs by definition, so under the requirement to exhibit a specific reduction, the correct finding is no significant circularity.

Assumptions & free parameters 2 free parameters · 5 assumptions · 0 invented entities

The central claim rests on the AutoDock Vina scoring function as a proxy for binding affinity, on static crystal structures with missing residues ignored, and on the unvalidated premise that a two-ligand MLSD score can be compared directly with a single-ligand inhibitor score. Grid placement, exhaustiveness, and run counts are unreported hand-chosen settings.

free parameters (2)
  • Grid box center and dimensions = Not reported
    Docking grid placement strongly affects Vina scores; the paper states grid dimensions were saved in config.txt but does not report them, so the central docking results depend on unreported hand-chosen coordinates.
  • Vina exhaustiveness and number of runs = Not reported
    Search effort and replicate count affect score convergence and the reported standard deviations; neither is given.
assumptions (5)
  • domain assumption AutoDock Vina scoring function estimates binding affinity
    All binding affinities are interpreted as inhibition strength; the paper never calibrates Vina scores against experimental binding data for these systems.
  • domain assumption Crystal structures 4GV1 and 4WJ9/8HOG represent relevant biological conformations
    Docking uses static PDB structures with water and co-crystallized ligands removed; missing residues are acknowledged as ignored.
  • domain assumption Rigid receptor approximation is adequate
    No side-chain flexibility or induced fit is modeled; the authors note this indirectly by recommending MD simulations in future work.
  • ad hoc to paper An MLSD complex score is comparable to a single-ligand inhibitor score
    The key inference in Results III-B treats two-ligand docking energy as directly beating one-ligand energy, which does not establish synergy or enhanced inhibition.
  • ad hoc to paper One inter-ligand pi-alkyl interaction implies synergistic stabilization
    The discussion attributes the enhanced effect to a single pi-alkyl contact without energetic decomposition or experimental support.

how reviews work

0 comments
Cite this review

Pith. "Pith review of Computational Analysis using Multi-ligand Simultaneous Docking of Withaferin A and Garcinol Reveals Enhanced BCL-2 and AKT-1 Inhibition." pith.science (2026). https://pith.science/paper/ICMLXKT5

@misc{pith2026250508632,
  author       = {Pith},
  title        = {Pith review of: Computational Analysis using Multi-ligand Simultaneous Docking of Withaferin A and Garcinol Reveals Enhanced BCL-2 and AKT-1 Inhibition},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/ICMLXKT5}},
  note         = {Machine review of arXiv:2505.08632}
}
read the original abstract

Developing an effective medicine to combat cancer and elusive stem cells is crucial in the current scenario. Withaferin A and Garcinol, important phytoconstituents of Withania somnifera (Ashwagandha) and Garcinia indica (Kokum) respectively, known for their therapeutic efficiency, have been used for several decades for treating various disorders, because of their anti-cancerous, anti-inflammatory and anti-invasive properties. This study investigates the potentials of withaferin A and garcinol in inhibiting BCL-2 and AKT-1, crucial proteins contributing in cancer cell persistence by evading apoptosis, increased cell proliferation, and inflammation. Molecular docking techniques, including single docking and MLSD, were used to understand the binding interaction of the ligands with BCL-2 and AKT-1. MLSD highlighted inter-ligand interactions among withaferin A and garcinol, against BCL-2, with a binding affinity of -11.88 +- 0.12 kcal/mol, surpassing the binding affinity of venetoclax (-9.73 +- 0.1 kcal/mol) a commercial inhibitor of BCL-2. For AKT-1, the binding affinity of withaferin A and garcinol (-13.74 +- 0.08 kcal/mol) surpassed the binding affinity of melatonin (-7.24 +- 0.06 kcal/mol), a commercial inhibitor of AKT-1. The MLSD results highlight the combined effects of garcinol and withaferin A, highlighting the importance of considering both the interactions of the bioactive compounds in the development of new medicines and strategies targeting cancer and elusive stem cells.

Figures

Figures reproduced from arXiv: 2505.08632 by the authors.

Figure 1
Figure 1. Methodology followed for docking Molecular docking was performed using the Vina Script method within a Conda environment accessed through Visual Studio Code. The resulting PDBQT files were analyzed in UCSF Chimera 1.17 and Discovery Studio 2021 Client to investigate binding pockets and amino acid interactions. The docking studies were executed on a server that featured 1.8 TiB storage capacity (1.7 TiB free), runnin… view at source ↗

Discussion (0). Continue with ORCID to comment.

Reference graph

Works this paper leans on

11 extracted references · 7 canonical work pages

  1. [1]

    Synthesis of Mechanism for single- and hybrid-tasks using Differential Evolution

    P. J. Trejo-Soto, A. Hernández-Campos, A. Romo-Mancillas, J. L. Medina-Franco,and R. Castillo, “In search of AKT kinase inhibitors as anticancer agents: structure based design, docking, and molecular dynamics studies of 2,4,6 -trisubstituted pyridines,” J. Biomol. Struct. Dyn, vol. 36, no. 2, pp. 423 –442, Feb. 2017, do i: 10.1080/07391102.2017.1285724

    work page Pith review arXiv 2017

  2. [2]

    Virtual Screening of Natural Compounds as Potential PI3K -AKT1 Signaling Pathway Inhibitors and Experimental Validation,

    S. Dotolo, C. Cervellera, M. Russo, G. L. Russo, and A. Facchiano, “Virtual Screening of Natural Compounds as Potential PI3K -AKT1 Signaling Pathway Inhibitors and Experimental Validation,” Molecules, vol. 26, no. 2, Jan. 2021, doi: 10.3390/molecules26020492

    work page doi:10.3390/molecules26020492 2021

  3. [3]

    Molecular docking studies of bioactive compounds from Annona muricata Linn as potential inhibitors for Bcl -2, Bcl -w and Mcl -1 antiapoptotic proteins,

    M. N. Mohamad Rosdi, S. Mohd Arif, M. H. Abu Bakar, S. A. Razali, R. Mohamed Zulkifli, and H. Ya’akob, “Molecular docking studies of bioactive compounds from Annona muricata Linn as potential inhibitors for Bcl -2, Bcl -w and Mcl -1 antiapoptotic proteins,” Apoptosis, vol. 23, no. 1, pp. 27 –40, Dec. 2017, doi: 10.1007/s10495- 017-1434-7

    work page doi:10.1007/s10495- 2017

  4. [4]

    The role of BCL-2 family proteins in regulating apoptosis and cancer therapy,

    S. Qian, Z. Wei, W. Yang, J. Huang, Y. Yang, and J. Wang, “The role of BCL-2 family proteins in regulating apoptosis and cancer therapy,” Front. Oncol, vol. 12, Oct. 2022, doi: 10.3389/fonc.2022.985363

    arXiv 2022

  5. [5]

    Mechanisms of action of the BCL -2 inhibitor venetoclax in multiple myeloma: a literature review,

    Q. Cao, X. Wu, Q. Zhang, J. Gong, Y. Chen, Y. You, J. Shen, Y. Qiang, and G. Cao, “Mechanisms of action of the BCL -2 inhibitor venetoclax in multiple myeloma: a literature review,” Front. Pharmacol, vol. 14, Nov. 2023. doi: 10.3389/fphar.2023.1291920

    arXiv 2023

  6. [6]

    Withaferin A Suppresses Anti -apoptotic BCL2, Bcl-xL, XIAP and Survivin Genes in Cervical Carcinoma Cells,

    L. Ye and Q. Song, “Withaferin A Suppresses Anti -apoptotic BCL2, Bcl-xL, XIAP and Survivin Genes in Cervical Carcinoma Cells,” Trop. J. Pharm. Res, vol. 14, no. 12, pp. 2201 –2206, Jan. 2016, doi: 10.4314/tjpr.v14i12.7

    work page doi:10.4314/tjpr.v14i12.7 2016

  7. [7]

    Garcinol Alone and in Combination With Cisplatin Affect Cellular Behavior and PI3K/AKT Protein Phosphorylation in Human Ovarian Cancer Cells,

    J. Zhang, H. Fang, J. Zhang, W. Guan, and G. Xu, “Garcinol Alone and in Combination With Cisplatin Affect Cellular Behavior and PI3K/AKT Protein Phosphorylation in Human Ovarian Cancer Cells,” Dose-Response, vol. 18, no. 2, Apr. 2020, doi: 10.1177/1559325820926732

    work page doi:10.1177/1559325820926732 2020

  8. [8]

    Identification of potential anticancer phytochemicals against colorectal cancer by structure-based docking studies,

    S. S. Qawoogha and A. Shahiwala, “Identification of potential anticancer phytochemicals against colorectal cancer by structure-based docking studies,” J. Recept. Signal. Transduct, vol. 40, no. 1, pp. 67 – 76, Jan. 2020, doi: 10.1080/10799893.2020.1715431

    arXiv 2020

Show all 11 references
  1. [9]

    Multiple ligand simultaneous docking: Orchestrated dancing of ligands in binding sites of protein,

    H. Li and C. Li, “Multiple ligand simultaneous docking: Orchestrated dancing of ligands in binding sites of protein,” J. Comput. Chem, vol. 31, no. 10, pp. 2014–2022, Jul. 2010, doi: 10.1002/jcc.21486

    2014 doi

  2. [10]

    Dual synergistic inhibition of COX and LOX by potential chemicals from Indian daily spices investigated through detailed computational studies,

    M. Rudrapal, W. A. Eltayeb, G. Rakshit, A. A. El-Arabey, J. Khan, S. M. Aldosari, B. Alshehri, and M. Abdalla, “Dual synergistic inhibition of COX and LOX by potential chemicals from Indian daily spices investigated through detailed computational studies,” Sci. Rep, vol. 13, n...

    2023 doi

  3. [11]

    Synergistic antitumor effect of 5-fluorouracil and withaferin-A induces endoplasmic reticulum stress- mediated autophagy and apoptosis in colorectal cancer cells,

    A. M. Alnuqaydan and S. S. Chauhan, “Synergistic antitumor effect of 5-fluorouracil and withaferin-A induces endoplasmic reticulum stress- mediated autophagy and apoptosis in colorectal cancer cells,” Cancer. Lett, vol. 10, no. 3, pp. 799–815, Jan. 2020

    2020

Pith tools

Reviewed August 15, 2026 · model on record in the stance chip above.